An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2

Inclusion Criteria

• •1. Male and female participants ≥ 18 years of age;
• •2. Has a diagnosis of type 2 diabetes mellitus (T2DM)
• •3. Participants with:
• •* newly diagnosed diabetes mellitus (DM) type 2 (drug naïve) or
• •* inadequate glycemic control on previously prescribed any oral antidiabetic drug.
• •4. VIPIDIA® is prescribed according to the approved label for the Russian Federation.
• •5. The participant's physician decides to prescribe VIPIDIA®:
• •* as monotherapy or
• •* as a part of combination therapy.
• •6. The participant (or, when applicable, the participant's legally acceptable representative) signs and dates a written, informed consent form prior to the start of data collection. Participant is capable of understanding the written informed consent, provides signed and written informed consent, and agrees to comply with protocol requirements. In case the participant is blind or unable to read, informed consent will also be witnessed.